Design and characterization of stabilized mutants of the SARS-CoV-2 receptor binding domain (Record no. 432571)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02253nam a22002057a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240809b |||||||| |||| 00| 0 eng d |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.91 |
| Item number | KHA |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Khan, Mohammad Suhail |
| 245 ## - TITLE STATEMENT | |
| Title | Design and characterization of stabilized mutants of the SARS-CoV-2 receptor binding domain |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc | Bangalore : |
| Name of publisher, distributor, etc | Indian Institute of Science, |
| Date of publication, distribution, etc | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 175. : |
| Other physical details | col. ill. |
| Accompanying material | e- Thesis. |
| Size of unit | 6.197 Mb. |
| 500 ## - GENERAL NOTE | |
| General note | Includes references. |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | PhD;2024,Molecular Biophysics Unit. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | The global pandemic caused by SARS-CoV-2 has resulted in millions of deaths worldwide, highlighting the urgent need for effective vaccines. The trimeric spike glycoprotein, particularly the receptor-binding domain (RBD), is a key target for neutralizing antibodies. Glycosylation of viral proteins, including the RBD, plays critical roles in viral pathobiology, immune evasion, and vaccine development. Our study investigates the role of N-linked glycans on RBD stability and immunogenicity, comparing proteins expressed in Pichia and mammalian cells. Through second-site saturation-suppressor mutagenesis (SSSM), stabilizing mutations in the RBD are identified, enhancing thermal stability, and facilitating mass production. Vaccination studies demonstrate that stabilized RBD proteins induce neutralizing antibodies against variants, with mammalian-expressed versions offering broader protection. Additionally, glycan removal impacts virus infectivity and antibody neutralization, while different glycan types have influenced immunogen localization and immune responses. Engineering Pichia strain to mimic mammalian-type complex N-linked glycans holds promise for enhancing subunit vaccine efficacy. Moreover, trimeric RBD formulations with various adjuvants elicit robust B and T-cell responses in comparison to monomeric RBD. These findings underscore the importance of glycosylation in vaccine design and highlight a promising RBD vaccine candidate with enhanced stability, immunogenicity, and choice of adjuvants offering insights for future vaccine development against emerging viral threats. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Vaccine |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Glycan |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | SARS-CoV-2 |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | Advised by Varadarajan, Raghavan. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | Thesis |
No items available.
